Oct. 28, 2025
| Today’s news and insights for biopharma leaders
The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three years of slow uptake for a medicine once viewed as a future blockbuster.
|
With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag “tolerizing” antigens to the thymus.
|
The results could help expand use of Welireg, one of the medicines Merck is counting on to drive revenue growth when its top-selling immunotherapy Keytruda loses patent protection.
|
As healthcare grows more complex, community pharmacies can help simplify and coordinate patient care.
|
News roundup
Incyte axed three prospects to focus on “high-value programs,” its CEO said. Elsewhere, MapLight priced an IPO during the federal government shutdown and GSK picked up a cancer drug.
|
UPDATED
MapLight Therapeutics priced a $251 million IPO on Sunday with the help of a little-used regulatory workaround enabling it to go public during a federal government shutdown.
|
A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver stress, prompting the company to pause enrollment and dosing while evaluating a new safety protocol.
|
|
While DNA and RNA still prevail, proteins, metabolites and other data types are growing in importance. Learn how to generate and integrate different dimensions of multimodal data in drug discovery in this playbook.
|
|
From Our Library
Playbook
Custom content for Woven Health Collective
|
Playbook
Custom content for MMS Holdings Inc.
|
Trendline
Supported by Covaris
|
< | 
